MedTrace Logo

Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder

NCT00479505 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2011-03-23

No results posted yet for this study

Summary

This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder. Patients will complete a series of questionnaires before treatment, during treatment and after treatment, to assess whether UK-369,003 has improved their symptoms of overactive bladder and erectile function.

Conditions

  • Urinary Bladder, Overactive

Interventions

DRUG

UK-369,003

UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Australia
  • Canada
  • Chile
  • Colombia
  • Finland
  • France
  • Germany
  • Greece
  • Italy
  • Latvia
  • Norway
  • Poland
  • Slovakia
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00479505 on ClinicalTrials.gov